Cubist, Teva Settle IP Suit Over Generic Cubicin

Law360, New York (April 4, 2011, 5:46 PM EDT) -- Cubist Pharmaceuticals Inc. struck a licensing deal with Teva Pharmaceutical Industries Ltd. on Monday to resolve patent infringement litigation over a proposed generic version of Cubist's IV antibiotic Cubicin, allowing Teva to roll out its generic by 2018.

The agreement would end Cubist's suit against Teva in the U.S. District Court for the District of Delaware alleging Teva infringed three patents, two titled “Methods for administration of antibiotics,” which expire in 2019, and one named “Anhydro-and isomer-A-21978C cyclic peptides,” which expires in 2016.

The agreement is...
To view the full article, register now.